pharma · Friedreich Ataxia · LRMR
Larimar Therapeutics trial registry — 6 ClinicalTrials.gov studies with program phase, status, and indication context.
Registry index of 6 ClinicalTrials.gov studies linked to Larimar Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Larimar Therapeutics trial registry — 6 ClinicalTrials.gov studies with program phase, status, and indication context.
Latest clinical program signals indexed for Larimar Therapeutics.
Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.